Dr. Darrell Wilcox · Medical Director

Is Pentadeca Arginate (PDA) the Same Thing as BPC-157?

Quick Answer

Yes, structurally. Pentadeca Arginate and BPC-157 are the same 15-amino-acid peptide. The only proposed difference is the salt used to stabilize it in solution: BPC-157 has conventionally been supplied as an acetate salt, while PDA uses an arginine salt instead. Swapping salt forms is a real and sometimes clinically meaningful pharmaceutical strategy, but no published data has tested whether this particular swap changes anything about how the peptide behaves in the body.

The Salt-Form Difference, Explained

Peptides intended for research or clinical use are almost always manufactured as a salt, meaning the peptide is paired with a counterion that improves its stability and solubility. Acetate has been the default counterion for BPC-157. Pentadeca Arginate substitutes arginine for that role instead. This isn't an invented distinction. A patented process for producing arginine (and lysine) salts of this exact pentadecapeptide exists (US Patent 9,850,282), so the underlying chemistry of the swap is real, documented, and has prior art. Salt-form changes are a legitimate and common strategy elsewhere in pharmacology, and they can genuinely alter solubility, stability, and absorption kinetics without changing the parent molecule's biological target.

Compounding pharmacies market the arginate form as more stable, which is the stated reasoning for making this particular swap. That's a reasonable hypothesis given the general principle above, but I haven't seen independent, peer-reviewed testing confirming it for this specific formulation. Until that exists, I'd treat the improved-stability claim as plausible rather than proven.

BPC-157's mechanism and human evidence are the same either way, since PDA is the same molecule. I cover that full picture, angiogenesis, nitric oxide signaling, the single-lab evidence concern, and what human data actually exists, on the BPC-157 Knowledge Center guide rather than repeating it here.

Any patient who competes in a tested sport should know that BPC-157 is on WADA's prohibited list under its S0 category for non-approved substances, and PDA carries that same status since it's the same peptide.

If you're already a patient at one of my clinics, bring this up with your care team directly rather than sourcing either product on your own. If you'd like an in-clinic consultation, here are all of the practices I see patients in. Prefer to start with a question first? Reach out directly by email or Instagram.

View My Clinic Locations

Or email drwilcox@precisionhormoneconsulting.com · DM @wellnessdoc_4everyoung on Instagram

— Dr. Darrell Wilcox · @wellnessdoc_4everyoung on Instagram

References

Stable pentadecapeptide salts, a process for preparation thereof, and their use in pharmaceutical preparations and therapy. US Patent 9,850,282 B2. Describes arginine and lysine salt forms of the same pentadecapeptide sequence underlying BPC-157.

This content is for educational purposes only and does not constitute medical advice. Neither BPC-157 nor Pentadeca Arginate is FDA-approved for any indication. Athletes subject to anti-doping testing should confirm current WADA and governing-body rules before using either product. Individual clinical decisions require physician evaluation and are made on a case-by-case basis. Dr. Wilcox is licensed to practice in multiple states. See About for current licensure.